Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A
Go back to Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A| Beam Inc. (NASDAQ: BEAM) | Delayed: 24.67 +1.57 (6.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.10 | 52 Week High | $83.60 | |||
| Open | $24.28 | 52 Week Low | $82.96 | |||
| Day High | $25.50 | P/E | 11.01 | |||
| Day Low | $24.05 | EPS | $2.24 | |||
| Volume | 2,425,462 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 24.67 +1.57 (6.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.10 | 52 Week High | $83.60 | |||
| Open | $24.28 | 52 Week Low | $82.96 | |||
| Day High | $25.50 | P/E | 11.01 | |||
| Day Low | $24.05 | EPS | $2.24 | |||
| Volume | 2,425,462 | |||||
